Details of the Drug

General Information of Drug (ID: DMMBQ20)

Drug Name
CPI-818
Indication
Disease Entry ICD 11 Status REF
T-cell lymphoma 2A90 Phase 1 [1]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
134517711
TTD ID
D1YZ5O

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific kinase (ITK) TT3C80U ITK_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03952078) A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.